



DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration
Silver Spring MD 20993

NDA 18461/S-055

SUPPLEMENT APPROVAL

Baxter Healthcare Corporation
Attention: Linda Coleman
Director, Global Regulatory Affairs
1620 Waukegan Road, MPGR-AL
McGaw Park, IL 60085

Dear Ms. Coleman:

Please refer to your Supplemental New Drug Application (sNDA) dated February 27, 2009, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Lidocaine in 5% Dextrose Injection, USP in plastic container.

We also refer to your amendment dated September 8, 2011, which constituted a complete response to our September 10, 2009, action letter.

This "Prior Approval" supplemental new drug application provides for revised container and overwrap labels.

We have completed our review of this supplemental application. It is approved, effective on the date of this letter.

CARTON AND IMMEDIATE CONTAINER LABELS

Submit final printed carton and container labels that are identical to the carton and immediate container labels submitted on September 8, 2011, as soon as they are available, but no more than 30 days after they are printed.

PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit the following, in triplicate, (1) a cover letter requesting advisory comments, (2) the proposed materials in draft or mock-up form with annotated references, and (3) the package insert(s) to:

Food and Drug Administration
Center for Drug Evaluation and Research
Office of Prescription Drug Promotion (OPDP)
5901-B Ammendale Road
Beltsville, MD 20705-1266

You must submit final promotional materials and package insert(s), accompanied by a Form FDA 2253, at the time of initial dissemination or publication [21 CFR 314.81(b)(3)(i)]. Form FDA 2253 is available at <http://www.fda.gov/opacom/morechoices/fdaforms/cder.html>; instructions are provided on page 2 of the form. For more information about submission of promotional materials to the Office of Prescription Drug Promotion (OPDP), see <http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm>.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, please call Russell Fortney, Regulatory Project Manager, at (301) 796-1068.

Sincerely,

{See appended electronic signature page}

Mary Ross Southworth, Pharm.D.
Deputy Director for Safety
Division of Cardiovascular and Renal Products
Office of Drug Evaluation I
Center for Drug Evaluation and Research

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

MARY R SOUTHWORTH
02/27/2012